Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, has received a Canadian ...

Add Yahoo as a preferred source to see more of our stories on Google. A decade of patient follow-up finds a combo of two immunotherapy drugs can greatly extend survival for people with advanced ...

An innovative treatment for bladder cancer successfully prevented the recurrence of tumors and improved survival rates following surgery.

A two-drug combination (zanzalintinib plus atezolizumab) improved survival for metastatic colon cancer patients who already ...

Some people with early stage cancers may be able to skip surgery after being treated with the immunotherapy drug dostarlimab, ...

New findings from a clinical trial highlight the potential for neoadjuvant immunotherapy to eliminate the need for surgery in patients with a particular type of cancer, helping them maintain a higher ...

The FDA rejected the promising skin cancer drug RP1 twice, leaving many puzzled and worried about what this means for other ...

Every participant in a new bowel cancer immunotherapy trial remained cancer-free nearly three years after receiving ...

The FDA’s Oncologic Drugs Advisory Committee has voted to restrict the use of nivolumab and pembrolizumab immunotherapy drugs based on the programmed death-ligand 1 expression levels of patients, ...

Pancreatic ductal adenocarcinoma is one of the deadliest cancer types, with a five-year survival rate of 13%. There are only ...

Health minister hopes a key injectable cancer drug will be available in all five trusts "as soon as possible".

Trying pollen seasons are becoming the norm in Western Pennsylvania. In March, TribLive reported that allergy season is ...